Sara M Federico
Overview
Explore the profile of Sara M Federico including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
786
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xie J, Mellado-Lagarde M, Blankenship K, Ganguly D, Twarog N, Bianski B, et al.
Cancer Sci
. 2025 Mar;
PMID: 40069935
Although primary tumor control rates after surgery and/or radiation therapy (RT) are generally high in patients with Ewing sarcoma (EWS), those with unresectable tumors have failure rates approaching 30% and...
2.
Lei S, Jia S, Takalkar S, Chang T, Ma X, Szlachta K, et al.
Leukemia
. 2024 Nov;
39(2):420-430.
PMID: 39523434
The utility of circulating tumor DNA (ctDNA) analysis has not been well-established for disease detection and monitoring of childhood cancers, especially leukemias. We developed PeCan-Seq, a deep sequencing method targeting...
3.
Lilley M, Salek M, Holland A, Inaba H, Federico S
Pediatr Blood Cancer
. 2024 Sep;
71(12):e31313.
PMID: 39289847
No abstract available.
4.
Nair S, Selvo N, Stolarski A, Klee B, Federico S, Stewart C
J Chromatogr B Analyt Technol Biomed Life Sci
. 2024 Aug;
1245:124273.
PMID: 39146822
Preclinical studies have demonstrated that liposomal irinotecan (CPT-11), a topoisomerase I inhibitor, has broad activity against adult cancers, including pancreatic, gastric, colon, lung, glioma, ovarian, and breast cancer. Encapsulation of...
5.
Cupit-Link M, Hagiwara K, Nagy M, Koo S, Orr B, Ruppin E, et al.
N Engl J Med
. 2024 Aug;
391(7):659-661.
PMID: 39141861
No abstract available.
6.
Kirk A, Crawford J, Chou C, Guy C, Pandey K, Kozlik T, et al.
Cell Rep Med
. 2024 Mar;
5(3):101469.
PMID: 38508137
Fibrolamellar carcinoma (FLC) is a liver tumor with a high mortality burden and few treatment options. A promising therapeutic vulnerability in FLC is its driver mutation, a conserved DNAJB1-PRKACA gene...
7.
Cupit-Link M, Federico S
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760578
Administration of chemoimmunotherapy using concurrent chemotherapy and an anti-GD2 monoclonal antibody (mAb), dinutuximab (DIN), demonstrated efficacy for the treatment of relapsed and refractory neuroblastoma. Chemoimmunotherapy, using a humanized anti-GD2 mAb,...
8.
Cupit-Link M, Hagiwara K, Zhang J, Federico S
Res Sq
. 2023 Aug;
PMID: 37645774
Despite advances in the treatment of high-risk neuroblastoma, approximately half of these patients die from the disease. Targeted therapy based on synthetic lethality associated with homologous recombination deficiency (HRD) caused...
9.
Badawi M, Menon R, Place A, Palenski T, Sunkersett G, Arrendale R, et al.
J Cancer
. 2023 May;
14(7):1151-1156.
PMID: 37215448
Infiltration of malignant cells into the central nervous system in hematological malignancies correlates with poor clinical outcomes. Investigations into the penetration of venetoclax into the central nervous system have been...
10.
Lerman B, Li Y, Carlowicz C, Granger M, Cash T, Sadanand A, et al.
J Clin Oncol
. 2022 Oct;
41(3):508-516.
PMID: 36206505
Purpose: Although chemoimmunotherapy is widely used for treatment of children with relapsed high-risk neuroblastoma (HRNB), little is known about timing, duration, and evolution of response after irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF)...